A recent study published in the New England of Medicine found that daily consumption of an omega-3-enriched margarine spread containing roughly 400 mg of EPA/DHA showed no benefit in preventing cardiovascular events for those having suffered a heart attack more than four years ago. The study's authors have stated that such findings may have been affected by multiple unique variables, most notably the administration of cholesterol and blood pressure lowering treatments to all subjects during the study's duration.
Another factor likely to have affected outcomes is the relatively low daily dose of EPA/DHA omega-3s, says Adam Ismail, executive director of the Global Organization for EPA and DHA Omega-3 (GOED), which represents more than 85 companies that provide high-quality omega-3 products to the international market. Ismail notes that this lower-dose study should not negate the positive findings of previous studies examining EPA/DHA's effect on secondary prevention in heart health at higher doses.
"GOED supports research that examines all health effects of consuming EPA and DHA-rich sources, as our members' focus is on educating consumers on the complexities of EPA/DHA consumption," says Ismail. "While 400 mg of combined EPA/DHA provides a sufficient dose for most healthy individuals, previous clinical studies in individuals having suffered a heart attack suggest that 1,000 mg+ of EPA/DHA decreases the incidence of secondary cardiovascular events—more than twice the dose administered in the recently published study."
Ismail also notes, "GOED is hopeful that the study's results showing the positive effect of low-dose EPA/DHA on diabetic subjects will yield further examination."
For more information on effective EPA/DHA dosage guidelines, access to Purdue University's Omega-3 Learning Consortium and details on GOED's strict quality standards and ethical business standards, visit www.goedomega3.com.
More about GOED:
GOED is a proactive and accountable association of the world's finest processors, refiners, manufacturers, distributors, marketers, retailers and supporters of products containing Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) omega-3 fatty acids. The organization's objectives are to promote and protect the category, educate consumers about the health benefits of EPA/DHA, and work with government groups, the healthcare community and the industry, while setting high standards for our business sector. GOED and its members are committed to personal integrity, ethical corporate behavior, public safety and quality assurance. For more information, visit http://www.goedquality.com.